

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 17, 2003, 07:12:51 ; Search time 21.3206 Seconds
(without alignments)
118.747 Million cell updates/sec

Title: US-09-787-082-8

Perfect score: 119

Sequence: 1 GCCSNPVCHLEHSLNCTNG 19

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_101002:*

- 1: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
- 2: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
- 3: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
- 4: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
- 5: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
- 6: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
- 7: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
- 8: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
- 9: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
- 10: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
- 11: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
- 12: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
- 13: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
- 14: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
- 15: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
- 16: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
- 17: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
- 18: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
- 19: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
- 20: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
- 21: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
- 22: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
- 23: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	119	100.0	19	21	AA1980
2	113	95.0	19	21	AA1981
3	102	85.7	16	16	AA1982
4	102	85.7	16	16	AA1983
5	102	85.7	16	16	AA1984
6	102	85.7	16	16	AA1985
7	102	85.7	16	16	AA1986
8	102	85.7	16	16	AA1987
9	102	85.7	16	16	AA1988
10	102	85.7	16	16	AA1989

11	102	85.7	17	20	AA1980
12	102	85.7	41	21	AA1981
13	102	85.7	63	21	AA1982
14	102	85.7	63	21	AA1983
15	100	84.0	63	21	AA1984
16	93	78.2	16	18	AA1985
17	92	77.3	41	21	AA1986
18	88	73.9	60	21	AA1987
19	87	73.1	16	21	AA1988
20	85	71.4	16	21	AA1989
21	82	68.9	16	20	AA1990
22	80	67.2	41	21	AA1991
23	79	66.4	38	21	AA1992
24	78	65.5	16	21	AA1993
25	78	65.5	41	21	AA1994
26	75	63.0	16	20	AA1995
27	73	61.3	20	21	AA1996
28	70	58.8	20	21	AA1997
29	69	58.0	40	21	AA1998
30	67	56.3	39	21	AA1999
31	67	56.3	60	21	AA2000
32	66	55.5	41	21	AA2001
33	65	54.6	16	16	AA2002
34	65	54.6	16	18	AA2003
35	65	54.6	16	18	AA2004
36	65	54.6	18	21	AA2005
37	65	54.6	25	21	AA2006
38	65	54.6	40	21	AA2007
39	65	54.6	41	21	AA2008
40	65	54.6	64	21	AA2009
41	64	53.8	20	21	AA2010
42	64	53.8	39	21	AA2011
43	64	53.8	39	21	AA2012
44	64	53.8	61	21	AA2013
45	63	52.9	40	21	AA2014

ALIGNMENTS

RESULT 1

AA1980

ID AA1980 standard; peptide; 19 AA.

XX

AC AA1980

XX

DT 25-JUL-2000 (first entry)

XX Amino acid sequence of a cyclised conotoxin peptide.

DE

XX Cyclised conotoxin; omega-conotoxin; neurological disorder; pain; stroke;
traumatic brain injury; migraine; epilepsy; Parkinson's disease;
Alzheimer's disease; multiple sclerosis; depression; alpha-conotoxin;
neuropsychiatric disorder; schizophrenia; Tourette's syndrome;
mu-conotoxin.

XX

OS Synthetic.

OS Conus sp.

XX

XX Key Location/Qualifiers

FT Misc-difference 1..19

FT Peptide /note= "peptide is cyclised via these residues"

FT Peptide /note= "conotoxin"

FT Peptide /note= "linker"

XX WO200015654-A1.

XX

XX 23-MAR-2000.

XX

XX 14-SEP-1999; 99WO-AU00769.

XX

XX

XX

XX

XX

XX

XX

XX

XX

```

PR 14-SEP-1998; 98AU-0005895.
XX (UYQU ) UNIV QUEENSLAND.
XX
XX Craik DJ, Daly NL, Nielsen KJ;
XX
XX WPI; 2000-271376/23.
XX
XX Novel cyclized conotoxin peptides useful in the therapeutic treatment
XX of diseases in humans -
XX
XX Claim 10; Page 31; 43pp; English.
XX
XX AAY84654-58 represent cyclised conotoxin peptides of the invention. The
XX cyclised peptides have improved properties, compared to their linear
XX counterparts. These include resistance to cleavage by proteases, high
XX chemical stability, improved biophysical properties, reduced side
XX effects and improved bioavailability. Cyclised omega-conotoxin peptides
XX block N-type calcium channels, and so may be useful in the treatment of
XX neurological disorders such as acute and chronic pain, stroke, traumatic
XX brain injury, migraine, epilepsy, Parkinson's disease, Alzheimer's
XX disease, multiple sclerosis, and depression. Alpha-conotoxins may be
XX useful in the treatment of neuropsychiatric disorders such as
XX schizophrenia, Parkinson's disease, Alzheimer's disease and Tourette's
XX syndrome. Mu-conotoxins interact with neuronal channels and may be used
XX to treat chronic and neuropathic pain. The cyclised conotoxin peptides
XX can be also used as neuropharmacological probes. Antibodies raised
XX against the peptides are useful as therapeutic or diagnostic agents,
XX and can be used to screen for the peptides.
XX
XX Sequence 19 AA;
SQ
Query Match 100.0%; Score 119; DB 21; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e-07;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 GCCSNPVCHEHSNLTNG 19
Db 1 GCCSNPVCHEHSNLTNG 19
RESULT 2
AAY84658
ID AAY84658 standard; peptide; 19 AA.
XX
XX AAY84658;
XX
XX 25-JUL-2000 (first entry)
XX
XX Amino acid sequence of a cyclised conotoxin peptide.
XX
XX Cyclised conotoxin; omega-conotoxin; neurological disorder; pain; stroke;
XX traumatic brain injury; migraine; epilepsy; Parkinson's disease;
XX Alzheimer's disease; multiple sclerosis; depression; alpha-conotoxin;
XX neuropsychiatric disorder; schizophrenia; Tourette's syndrome;
XX mu-conotoxin.
XX
XX Synthetic.
XX Conus sp.
XX
XX Key Location/Qualifiers
XX Misc-difference 1..19
XX /note= "peptide is cyclised via these residues"
XX Peptide 1..15
XX /note= "conotoxin"
XX Peptide 16..19
XX /note= "linker"
XX
XX WO200015654-A1.
XX
XX 23-MAR-2000.
XX
XX 14-SEP-1999; 99WO-AU00769.

```

```

XX 14-SEP-1998; 98AU-0005895.
XX (UYQU ) UNIV QUEENSLAND.
XX
XX Craik DJ, Daly NL, Nielsen KJ;
XX
XX WPI; 2000-271376/23.
XX
XX Novel cyclized conotoxin peptides useful in the therapeutic treatment
XX of diseases in humans -
XX
XX Claim 10; Page 31; 43pp; English.
XX
XX AAY84654-58 represent cyclised conotoxin peptides of the invention. The
XX cyclised peptides have improved properties, compared to their linear
XX counterparts. These include resistance to cleavage by proteases, high
XX chemical stability, improved biophysical properties, reduced side
XX effects and improved bioavailability. Cyclised omega-conotoxin peptides
XX block N-type calcium channels, and so may be useful in the treatment of
XX neurological disorders such as acute and chronic pain, stroke, traumatic
XX brain injury, migraine, epilepsy, Parkinson's disease, Alzheimer's
XX disease, multiple sclerosis, and depression. Alpha-conotoxins may be
XX useful in the treatment of neuropsychiatric disorders such as
XX schizophrenia, Parkinson's disease, Alzheimer's disease and Tourette's
XX syndrome. Mu-conotoxins interact with neuronal channels and may be used
XX to treat chronic and neuropathic pain. The cyclised conotoxin peptides
XX can be also used as neuropharmacological probes. Antibodies raised
XX against the peptides are useful as therapeutic or diagnostic agents,
XX and can be used to screen for the peptides.
XX
XX Sequence 19 AA;
SQ
Query Match 95.0%; Score 113; DB 21; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 2 CCSNPVCHEHSNLTNG 19
Db 1 CCSNPVCHEHSNLTNG 18
RESULT 3
AAY75279
ID AAY75279 standard; peptide; 16 AA.
XX
XX AAY75279;
XX
XX 21-DEC-1995 (first entry)
XX
XX A-lineage conotoxin MG-1 peptide.
XX
XX Conotoxin; neuromuscular; synapse; signal transmission; inhibitor.
XX Conus magus.
XX
XX Key Location/Qualifiers
XX Misc-difference 6
XX /label= Pro or OTHER
XX /note= "Hydroxyproline"
XX Modified-site 16
XX /note= "preferably amidated"
XX
XX WO9511256-A1.
XX
XX 27-APR-1995.
XX
XX 19-OCT-1994; 94WO-US11927.
XX
XX 19-OCT-1993; 93US-0137800.
XX
XX (UTAH ) UNIV UTAH RES FOUND.
XX

```

PI Cruz LJ, Hillyard DR, McIntosh JM, Olivera BM, Santos AD;
 DR WPI; 1995-170189/22.
 XX
 XX New A-lineage conotoxin peptide(s) - which inhibit synaptic
 PT transmission at the neuromuscular junction or are active against
 PT potassium or sodium channels
 XX
 PS Claim 1; Page 43; 66pp; English.
 XX
 CC The kappa-conotoxin, alpha conotoxin and alpha-like conotoxin
 CC peptides all belong to a group of peptides known as the A-lineage
 CC conotoxin peptides. The A-lineage conotoxin peptides have a wide
 CC variety of pharmacological uses. The A-lineage conotoxin peptides
 CC claimed (AAR75264-R75293) are useful for the inhibition of synaptic
 CC transmission at neuromuscular junctions by blocking nicotinic acetyl
 CC choline receptors and they also have activity against voltage-gated Na
 CC and K channels.
 XX
 SQ Sequence 16 AA;
 Query Match 85.7%; Score 102; DB 16; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.4e-05;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCSNPVCHEHSNLC 16
 Db 1 GCCSNPVCHEHSNLC 16
 RESULT 4
 AAW24899
 ID AAW24899 standard; peptide; 16 AA.
 XX
 AC AAW24899;
 XX
 DT 15-OCT-1997 (first entry)
 DE Predatory cone snail venom alpha-conotoxin MII.
 XX
 KW Conotoxin; venom; predatory; cone snail; Conus; A-lineage; inhibitor;
 KW synaptic transmission; neuromuscular junction; block; alpha-conotoxin;
 KW nicotinic acetylcholine receptor; kappa-conotoxin; voltage-sensitive
 KW potassium CHANNEL; sodium channel.
 XX
 OS Conus magus.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 16
 XX /note= "amidated C-terminus"
 XX
 XX US5633347-A.
 PN 27-MAY-1997.
 XX
 PD 29-JUN-1993; 93US-0084848.
 PF 07-JUN-1995; 95US-0480750.
 PR 29-JUN-1993; 93US-0084848.
 PR 19-OCT-1993; 93US-0137800.
 XX
 PA (UTAH) UNIV UTAH RES FOUND.
 XX
 PI Cruz LJ, Hillyard DR, McIntosh JM, Olivera BM, Santos AO;
 XX WPI; 1997-309336/28.
 DR
 XX New kappa-conotoxin peptide(s) - present in venom of fish-hunting
 PT cone snail
 XX
 PS Disclosure; Column 6; 37pp; English.
 XX
 CC The peptides AAW24878-W24900 represent novel toxin peptides isolated

CC from the venom of various predatory cone snails of the genus Conus. The
 CC peptides are A-lineage conotoxin peptides which fall into 3 groups
 CC dependent on their amino acid sequences: (i) alpha-3/5 have a core
 CC sequence CCXXXCXXXXXC where X is any amino acid; (ii) alpha-4/7 have a
 CC core sequence CCXXXCXXXXXC; and (iii) kappa-7/2/1/3 have the core
 CC sequence CCXXXCXXXXXCXXXXC. The peptide presented here was isolated
 CC from Conus magus and falls into the alpha-4/7 category.
 CC Alpha-conotoxin peptides are potent inhibitors of synaptic transmission
 CC at the neuromuscular junction by blocking nicotinic acetylcholine
 CC receptors, whereas kappa-conotoxins have activities against
 CC voltage-sensitive potassium or sodium channels.
 XX
 SQ Sequence 16 AA;
 Query Match 85.7%; Score 102; DB 18; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.4e-05;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCSNPVCHEHSNLC 16
 Db 1 GCCSNPVCHEHSNLC 16
 RESULT 5
 AAW24886
 ID AAW24886 standard; peptide; 16 AA.
 XX
 AC AAW24886;
 XX
 DT 15-OCT-1997 (first entry)
 DE Predatory cone snail venom alpha-conotoxin MG-1.
 XX
 KW Conotoxin; venom; predatory; cone snail; Conus; A-lineage; inhibitor;
 KW synaptic transmission; neuromuscular junction; block; alpha-conotoxin;
 KW nicotinic acetylcholine receptor; kappa-conotoxin; voltage-sensitive
 KW potassium CHANNEL; sodium channel.
 XX
 OS Conus magus.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 16
 XX /note= "optionally 4Hyp"
 XX
 XX US5633347-A.
 PN 27-MAY-1997.
 XX
 PD 29-JUN-1993; 93US-0084848.
 PF 07-JUN-1995; 95US-0480750.
 PR 29-JUN-1993; 93US-0084848.
 PR 19-OCT-1993; 93US-0137800.
 XX
 PA (UTAH) UNIV UTAH RES FOUND.
 XX
 PI Cruz LJ, Hillyard DR, McIntosh JM, Olivera BM, Santos AO;
 XX WPI; 1997-309336/28.
 DR
 XX New kappa-conotoxin peptide(s) - present in venom of fish-hunting
 PT cone snail
 XX
 PS Disclosure; Column 5; 37pp; English.
 XX
 CC The peptides AAW24878-W24900 represent novel toxin peptides isolated
 CC from the venom of various predatory cone snails of the genus Conus. The
 CC peptides are A-lineage conotoxin peptides which fall into 3 groups
 CC dependent on their amino acid sequences: (i) alpha-3/5 have a core
 CC sequence CCXXXCXXXXXC where X is any amino acid; (ii) alpha-4/7 have a
 CC core sequence CCXXXCXXXXXC; and (iii) kappa-7/2/1/3 have the core
 CC sequence CCXXXCXXXXXCXXXXC. The peptide presented here was isolated
 CC from Conus magus and falls into the alpha-4/7 category.

CC Alpha-conotoxin peptides are potent inhibitors of synaptic transmission
CC at the neuromuscular junction by blocking nicotinic acetylcholine
CC receptors, whereas kappa-conotoxins have activities against
CC voltage-sensitive potassium or sodium channels.

XX SQ Sequence 16 AA;

Query Match 85.7%; Score 102; DB 18; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHLEHSLC 16
|||||

Db 1 GCCSNPVCHLEHSLC 16

RESULT 6

AAW12753
ID AAW12753 standard; Peptide; 16 AA.

XX AC AAW12753;

XX DT 16-APR-1997 (first entry)

XX DE A-lineage conotoxin peptide MII.

XX KW Polymerase chain reaction; PCR; primer: amplify; conotoxin; Conus;
KW inhibitor; synaptic transmission; neuromuscular junction; sodium channel;
KW nicotinic acetylcholine receptor; potassium channel; muscle relaxant;
KW myasthenia gravis; small cell lung cancer; therapy.

XX OS Conus magus.

XX FH Key Location/Qualifiers
XX FT Modified-site 16
FT /note= "amidated"

XX PN US5589340-A.

XX PD 31-DEC-1996.

XX PF 29-JUN-1993; 93US-0084848.

XX PR 07-JUN-1995; 95US-0477383.

XX PR 29-JUN-1993; 93US-0084848.

XX PR 19-OCT-1993; 93US-0137800.

XX PA (UTAH) UNIV UTAH RES FOUND.

XX PI Cruz LJ, Hillyard DR, McIntosh JM, Olivera BM, Santos AD;

XX DR WPI; 1997-076840/07.

XX PT Identifying nucleic acid encoding A-lineage conotoxin peptide(s) by
PT amplification - uses primers corresponding to conserved regions in
PT the signal sequence and 3'-untranslated regions, useful e.g. in
PT treatment of small cell lung cancer

XX PS Disclosure; Column 6; 36pp; English.

XX CC AAW12726-W12769 represent conotoxin peptides. This sequence represents
CC the A-lineage conotoxin MII peptide isolated from Conus magus. These
CC sequences are identified using the method of the invention. The method
CC of the invention is for identifying DNA encoding A-lineage conotoxin
CC peptides by subjecting Conus nucleic acid to amplification with primer
CC sequences (see AAT59714 and AAT59715). The primers are specific for the
CC signal sequence and 3'-untranslated (3'UTR) regions of the conotoxin
CC gene, which are highly homologous between conotoxins, and are therefore
CC suitable sites for detection. A-lineage conotoxins include alpha-
CC conotoxins, and kappa-conotoxins. Alpha-conotoxins are powerful
CC inhibitors of synaptic transmission at the neuromuscular junction, and
CC are usually nicotinic acetylcholine receptor blockers. Kappa-conotoxins
CC act on the voltage sensitive sodium and potassium channels. The

CC conotoxins identified can be used as muscle relaxants, in the diagnosis
CC of myasthenia gravis, and for the treatment or diagnosis of small cell
CC lung cancer. For the treatment of small cell lung cancer, the conotoxin
CC peptides act by binding to the nicotinic receptors, and thereby blocking
CC the nicotine/cytosine stimulated release of the mitogen
CC 5-hydroxytryptamine.

XX SQ Sequence 16 AA;

Query Match 85.7%; Score 102; DB 18; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHLEHSLC 16
|||||

Db 1 GCCSNPVCHLEHSLC 16

RESULT 7

AAW12741
ID AAW12741 standard; Peptide; 16 AA.

XX AC AAW12741;

XX DT 16-APR-1997 (first entry)

XX DE A-lineage conotoxin peptide MG-1.

XX KW Polymerase chain reaction; PCR; primer: amplify; conotoxin; Conus;
KW inhibitor; synaptic transmission; neuromuscular junction; sodium channel;
KW nicotinic acetylcholine receptor; potassium channel; muscle relaxant;
KW myasthenia gravis; small cell lung cancer; therapy.

XX OS Conus magus.

XX FH Key Location/Qualifiers
XX FT Modified-site 6
FT /note= "optionally hydroxylated"

XX FT Modified-site 16
FT /note= "amidated"

XX PN US5589340-A.

XX PD 31-DEC-1996.

XX PF 29-JUN-1993; 93US-0084848.

XX PR 07-JUN-1995; 95US-0477383.

XX PR 29-JUN-1993; 93US-0084848.

XX PR 19-OCT-1993; 93US-0137800.

XX PA (UTAH) UNIV UTAH RES FOUND.

XX PI Cruz LJ, Hillyard DR, McIntosh JM, Olivera BM, Santos AD;

XX DR WPI; 1997-076840/07.

XX PT Identifying nucleic acid encoding A-lineage conotoxin peptide(s) by
PT amplification - uses primers corresponding to conserved regions in
PT the signal sequence and 3'-untranslated regions, useful e.g. in
PT treatment of small cell lung cancer

XX PS Disclosure; Column 5; 36pp; English.

XX CC AAW12726-W12769 represent conotoxin peptides. This sequence represents
CC the A-lineage conotoxin MG-1 peptide isolated from Conus magus. These
CC sequences are identified using the method of the invention. The method
CC of the invention is for identifying DNA encoding A-lineage conotoxin
CC peptides by subjecting Conus nucleic acid to amplification with primer
CC sequences (see AAT59714 and AAT59715). The primers are specific for the
CC signal sequence and 3'-untranslated (3'UTR) regions of the conotoxin
CC gene, which are highly homologous between conotoxins, and are therefore
CC suitable sites for detection. A-lineage conotoxins include alpha-

CC conotoxins, and kappa-conotoxins. Alpha-conotoxins are powerful
CC inhibitors of synaptic transmission at the neuromuscular junction, and
CC are usually nicotinic acetylcholine receptor blockers. Kappa-conotoxins
CC act on the voltage sensitive sodium and potassium channels. The
CC conotoxins identified can be used as muscle relaxants, in the diagnosis
CC of myasthenia gravis, and for the treatment or diagnosis of small cell
CC lung cancer. For the treatment of small cell lung cancer, the conotoxin
CC peptides act by binding to the nicotinic receptors, and thereby blocking
CC the nicotine/cytosine stimulated release of the mitogen
CC 5-hydroxytryptamine.

XX
XX
SQ Sequence 16 AA;
Query Match 85.7%; Score 102; DB 18; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16
Db 1 GCCSNPVCHEHSNLC 16
|||||

RESULT 8
AAW57903
ID AAW57903 standard; peptide; 16 AA.

XX
AC AAW57903;

XX
DT 25-SEP-1998 (first entry)

XX
DE Conotoxin peptide MII.

XX
KW Conotoxin peptide; Iml; MII; cardiovascular agent; altered heart rate;
KW altered blood pressure; nicotinic acetylcholine receptor antagonist;
KW B neurone blocker; venom; marine snail; C neurone blocker;
KW sympathetic impulse.

XX
OS Conus imperialis.

XX
FH Key Location/Qualifiers
FT Disulfide-bond 2..8
FT Disulfide-bond 3..16

XX
PN WO9822126-A1.

XX
PD 28-MAY-1998.

XX
PF 17-NOV-1997; 97WO-US20669.

XX
PR 18-NOV-1996; 96US-0031141.

XX
PA (UTAH) UNIV UTAH RES FOUND.

XX
PI McIntosh JM, Olivera BM, Yoshikami D;

XX
DR WPI; 1998-322346/28.

XX
PT Use of the conotoxin peptide(s) Iml and MII - as agents which can
PT regulate heart rate or blood pressure

XX
PS Claim 1; Page 4; 24pp; English.

XX
CC This sequence represents the conotoxin peptide Iml. This sequence and
CC the MII conotoxin peptide (see AAW57903) can be used in the method of
CC the invention for the treatment of a patient who has an altered heart
CC rate or an altered blood pressure. The peptides are found in the venom of
CC marine snails of the genus Conus. They are active as nicotinic
CC acetylcholine receptor antagonists. They differentially block the B and C
CC neurones, and are thus able to differentially block sympathetic impulses
CC to the heart affecting the heart rate and blood pressure. The above
CC agents are capable of discretely affecting the heart rate or blood
CC pressure, without affecting other muscles.

XX

SQ Sequence 16 AA;

Query Match 85.7%; Score 102; DB 19; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16
Db 1 GCCSNPVCHEHSNLC 16
|||||

RESULT 9
AAY24167

XX
ID AAY24167 standard; peptide; 16 AA.

XX
AC AAY24167;

XX
DT 10-SEP-1999 (first entry)

XX
DE Alpha-conotoxin peptide SEQ ID NO:2.

XX
KW Alpha-conotoxin; neuronal nicotinic acetylcholine receptor; nAChR;
KW small cell lung carcinoma; cardiovascular disorder; nicotine addiction;
KW gastric motility disorder; urinary incontinence; mood disorder;
KW bipolar disorder; unipolar depression; dysthymia;
KW seasonal effective disorder.

XX
OS Conus magus.

XX
PN WO933482-A1.

XX
PD 08-JUL-1999.

XX
PF 23-DEC-1998; 98WO-US27367.

XX
PR 03-APR-1998; 98US-0080588.

XX
PR 31-DEC-1997; 97US-0070153.

XX
PA (UTAH) UNIV UTAH RES FOUND.

XX
PI Cartier GE, Luo S, McIntosh JM, Olivera BM, Yoshikami D;

XX
WPI; 1999-405367/34.

XX
PT Alpha-conotoxin peptides that are used to treat disorders regulated
PT at neuronal nicotinic acetylcholine receptors

XX
PS Disclosure; Page 6; 40pp; English.

XX
CC The present sequence represents an example of an alpha-conotoxin
CC peptide, which can be used to treat disorders regulated at neuronal
CC nicotinic acetylcholine receptors (nAChR). The alpha-conotoxins
CC are useful for preparing a pharmaceutical composition for treating
CC disorders regulated at neuronal nAChR, especially alpha 3 beta 2,
CC alpha 3 beta 4 or alpha 7-containing nAChR. Disorders that can be
CC treated include cardiovascular disorders, a gastric motility disorder,
CC urinary incontinence, nicotine addiction, a mood disorder or small cell
CC lung carcinoma. Mood disorders include bipolar disorder, unipolar
CC depression, dysthymia and seasonal effective disorder. The alpha-
CC conotoxins can also be used for diagnosis of small cell lung carcinoma.
CC The alpha-conotoxin antagonists are able to discriminate between non-
CC symmetrical ligand binding interfaces present on the nAChR. The alpha-
CC conotoxin has the ability to potentially block any receptor containing a
CC alpha beta subunit interface, regardless of what other subunits may be
CC present in the receptor complex.

SQ Sequence 16 AA;

Query Match 85.7%; Score 102; DB 20; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16

Db 1 GCCSNPVCHEHSNLC 16

RESULT 10
AA09520
ID AAY09520 standard; peptide; 16 AA.
AC AAY09520;
XX
XX 20-JUL-1999 (first entry)
DT
XX Alpha conopeptide MII SEQ ID NO:1.
DE
XX Alpha conopeptide MII: alpha-4/7 conotoxin; cardiovascular agent;
KW neuronal nicotinic acetylcholine receptor; small cell lung carcinoma;
KW detection; gastric motility; urinary incontinence; anti-smoking agent.
XX
OS Conus magus.
XX
FH Key Location/Qualifiers
FT Disulfide-bond 2..8
FT Disulfide-bond 3..16
XX
XX WO9921878-A1.
PN
XX
XX 06-MAY-1999.
PD
XX
XX 23-OCT-1998; 98WO-US22368.
PF
XX
XX 14-NOV-1997; 97US-0065814.
PR
XX 24-OCT-1997; 97US-0062783.
PR
XX (COGN-) COGNETIX INC.
PA (SALK) SALK INST.
PA (UYCA-) UNIV CASE WESTERN RESERVE.
PA (UTAH) UNIV UTAH RES FOUND.
XX
XX Cartier GE, Koerber SC, McIntosh JM, Olivera BM;
PI Rivier JE, Shen GS, Shonk, Yoshikami D;
XX
XX WPI; 1999-326687/27.
DR
XX
XX Derivatives of alpha-conotoxin and their analogues
PT
XX
PS Example 11; Page 51; 176pp; English.
XX
XX The present invention describes derivatives (I) of alpha-conotoxin MII
CC as (II), an alpha-4/7 conotoxin peptide, with practically the same activity
CC as (II). (I), and its mimetics, are useful as cardiovascular agents;
CC for treating or diagnosing small-cell lung carcinoma; and as gastric
CC motility, urinary incontinence and anti-smoking agents. (I) and their
CC mimetics can be designed to be selective for particular subtypes of
CC neuronal nicotinic acetylcholine receptor, particularly the alpha 3 beta
CC 2 and alpha 3 beta 4 subtypes. The present sequence represents the
CC alpha-conopeptide MII, which is used in an example from the present
XX invention.
XX
SQ Sequence 16 AA;
Query Match 85.7%; Score 102; DB 20; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16
Db 1 GCCSNPVCHEHSNLC 16

RESULT 11
AAY24156
ID AAY24156 standard; peptide; 17 AA.
XX

AC AAY24156;
XX
XX 10-SEP-1999 (first entry)
DE
XX Alpha-conotoxin peptide SEQ ID NO:3.
XX
KW Alpha-conotoxin; neuronal nicotinic acetylcholine receptor; nAChR;
KW small cell lung carcinoma; cardiovascular disorder; nicotine addiction;
KW gastric motility disorder; urinary incontinence; mood disorder;
KW bipolar disorder; unipolar depression; dysthymia;
KW seasonal effective disorder.
XX
XX Conus magus.
OS Synthetic.
OS
XX WO9933482-A1.
PN
XX
XX 08-JUL-1999.
PD
XX
XX 23-DEC-1998; 98WO-US27367.
PF
XX
XX 03-APR-1998; 98US-0080588.
PR
XX 31-DEC-1997; 97US-0070153.
PR
XX (UTAH) UNIV UTAH RES FOUND.
PA
XX
XX Cartier GE, Luo S, McIntosh JM, Olivera BM, Yoshikami D;
PI WPI; 1999-405367/34.
XX
XX Alpha-conotoxin peptides that are used to treat disorders regulated
PT at neuronal nicotinic acetylcholine receptors
PT
XX
XX Claim 12; Page 27; 40pp; English.
XX
XX The present sequence represents a specifically claimed example of an
CC alpha-conotoxin from the general formula given in AAY24155, which can be
CC used to treat disorders regulated at neuronal nicotinic acetylcholine
CC receptors (nAChR). The alpha-conotoxins are useful for preparing a
CC pharmaceutical composition for treating disorders regulated at neuronal
CC nAChR, especially alpha 3 beta 2, alpha 3 beta 4 or alpha 7-containing
CC nAChR. Disorders that can be treated include cardiovascular disorders, a
CC mood disorder or small cell lung carcinoma. Mood disorders include
CC bipolar disorder, unipolar depression, dysthymia and seasonal effective
CC disorder. The alpha-conotoxins can also be used for diagnosis of small
CC cell lung carcinoma. The alpha-conotoxin antagonists are able to
CC discriminate between non-symmetrical ligand binding interfaces present
CC on the nAChR. The alpha-conotoxin has the ability to potentially block any
CC receptor containing an alpha beta subunit interface, regardless of what
CC other subunits may be present in the receptor complex.
XX
SQ Sequence 17 AA;
Query Match 85.7%; Score 102; DB 20; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16
Db 2 GCCSNPVCHEHSNLC 17

RESULT 12
AAB21579
ID AAB21579 standard; Peptide; 41 AA.
XX
XX AAB21579;
AC
XX
XX 19-JAN-2001 (first entry)
DT
XX Cone snail alpha-conotoxin SEQ ID NO: 286.
DE
XX

KW Cone snail; alpha-conotoxin; venom; disulphide bond; mood disorder;
 KW neuronal nicotinic acetylcholine receptor; cardiovascular disorder;
 KW gastric motility disorder; urinary incontinence; nicotine addiction;
 KW small cell lung carcinoma.

XX Conus achatinus.

XX WO200044776-A1.

XX 03-AUG-2000.

XX 28-JAN-2000; 2000WO-US01979.

XX 29-JAN-1999; 99US-0118381.

XX (UTAH) UNIV UTAH RES FOUND.

XX (COGN-) COGNETIX INC.

XX Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM;

XX WPI; 2000-505965/45.

XX N-PSDB; AAA89475.

XX alpha-conotoxin polypeptides derived from the venom of cone snails
 PT useful e.g. as neuromuscular blocking agents for use in surgery and for
 PT treating unipolar depression -

PS Claim 39; Page 52; 229pp; English.

XX The present invention relates to a number of alpha-conotoxin peptides and
 CC their coding sequences from a number of different species of cone snail.
 CC These peptides are found in minute quantities in the venom of the snails,
 CC and are targeted at the neuronal nicotinic acetylcholine receptors of the
 CC nervous system. They usually contain two disulphide bonds, which give
 CC them defined conformations, a rarity in molecules this small. The
 CC alpha-conotoxins can be used as neuromuscular blocking agents in surgery,
 CC and for treating disorders regulated at the neuronal nicotinic
 CC acetylcholine receptors, including cardiovascular disorders, gastric
 CC motility disorders, urinary incontinence, nicotine addiction, mood
 CC disorders such as bipolar disorder, unipolar depression, dysthymia and
 CC seasonal affective disorder, and small cell lung carcinoma.

XX Sequence 41 AA;

Query Match 85.7%; Score 102; DB 21; Length 41;

Best Local Similarity 100.0%; Pred. No. 5.4e-05;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16

DB 22 GCCSNPVCHEHSNLC 37

RESULT 13

AAB21426

ID AAB21426 standard; Protein; 63 AA.

XX AAB21426;

XX 19-JAN-2001 (first entry)

XX Cone snail alpha-conotoxin SEQ ID NO: 59.

XX Cone snail; alpha-conotoxin; venom; disulphide bond; mood disorder;
 KW neuronal nicotinic acetylcholine receptor; cardiovascular disorder;
 KW gastric motility disorder; urinary incontinence; nicotine addiction;
 KW small cell lung carcinoma.

XX Conus magus.

XX WO200044776-A1.

XX 03-AUG-2000.

XX 28-JAN-2000; 2000WO-US01979.

XX 29-JAN-1999; 99US-0118381.

XX (UTAH) UNIV UTAH RES FOUND.

XX (COGN-) COGNETIX INC.

XX Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM;

XX WPI; 2000-505965/45.

XX N-PSDB; AAA89401.

XX alpha-conotoxin polypeptides derived from the venom of cone snails
 PT useful e.g. as neuromuscular blocking agents for use in surgery and for
 PT treating unipolar depression -

PS Claim 39; Page 31; 229pp; English.

XX The present invention relates to a number of alpha-conotoxin peptides and
 CC their coding sequences from a number of different species of cone snail.
 CC These peptides are found in minute quantities in the venom of the snails,
 CC and are targeted at the neuronal nicotinic acetylcholine receptors of the
 CC nervous system. They usually contain two disulphide bonds, which give
 CC them defined conformations, a rarity in molecules this small. The
 CC alpha-conotoxins can be used as neuromuscular blocking agents in surgery,
 CC and for treating disorders regulated at the neuronal nicotinic
 CC acetylcholine receptors, including cardiovascular disorders, gastric
 CC motility disorders, urinary incontinence, nicotine addiction, mood
 CC disorders such as bipolar disorder, unipolar depression, dysthymia and
 CC seasonal affective disorder, and small cell lung carcinoma.

XX Sequence 63 AA;

Query Match 85.7%; Score 102; DB 21; Length 63;

Best Local Similarity 100.0%; Pred. No. 7.7e-05;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCSNPVCHEHSNLC 16

DB 44 GCCSNPVCHEHSNLC 59

RESULT 14

AAB21473

ID AAB21473 standard; Protein; 63 AA.

XX AAB21473;

XX 19-JAN-2001 (first entry)

XX Cone snail alpha-conotoxin SEQ ID NO: 153.

XX Cone snail; alpha-conotoxin; venom; disulphide bond; mood disorder;
 KW neuronal nicotinic acetylcholine receptor; cardiovascular disorder;
 KW gastric motility disorder; urinary incontinence; nicotine addiction;
 KW small cell lung carcinoma.

XX Conus consors.

XX WO200044776-A1.

XX 03-AUG-2000.

XX 28-JAN-2000; 2000WO-US01979.

XX 29-JAN-1999; 99US-0118381.

XX (UTAH) UNIV UTAH RES FOUND.

XX (COGN-) COGNETIX INC.

XX Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM;

DR WPI; 2000-505965/45.
 DR N-PSDB; AAA89448.
 XX
 PT alpha-conotoxin polypeptides derived from the venom of cone snails
 PT useful e.g. as neuromuscular blocking agents for use in surgery and for
 PT treating unipolar depression -
 XX
 PS Claim 39; Page 45; 229pp; English.
 XX
 CC The present invention relates to a number of alpha-conotoxin peptides and
 CC their coding sequences from a number of different species of cone snail.
 CC These peptides are found in minute quantities in the venom of the snails,
 CC and are targeted at the neuronal nicotinic acetylcholine receptors of the
 CC nervous system. They usually contain two disulphide bonds, which give
 CC them defined conformations, a rarity in molecules this small. The
 CC alpha-conotoxins can be used as neuromuscular blocking agents in surgery,
 CC and for treating disorders regulated at the neuronal nicotinic
 CC acetylcholine receptors, including cardiovascular disorders, gastric
 CC motility disorders, urinary incontinence, nicotine addiction, mood
 CC disorders such as bipolar disorder, unipolar depression, dysthymia and
 CC seasonal affective disorder, and small cell lung carcinoma.
 XX
 SQ Sequence 63 AA;
 Query Match 85.7%; Score 102; DB 21; Length 63;
 Best Local Similarity 100.0%; Pred. No. 7.7e-05;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCSNPVCCHLEHSNLC 16
 Db 44 GCCSNPVCCHLEHSNLC 59
 RESULT 15
 AAB21448
 ID AAB21448 standard; Protein; 63 AA.
 XX
 AC AAB21448;
 XX
 DT 19-JAN-2001 (first entry)
 XX
 DE Cone snail alpha-conotoxin SEQ ID NO: 103.
 XX
 KW Cone snail; alpha-conotoxin; venom; disulphide bond; mood disorder;
 KW neuronal nicotinic acetylcholine receptor; cardiovascular disorder;
 KW gastric motility disorder; urinary incontinence; nicotine addiction;
 KW small cell lung carcinoma.
 XX
 OS Conus stercusmuscarum.
 OS
 PN WO200044776-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 28-JAN-2000; 2000WO-US01979.
 XX
 PR 29-JAN-1999; 99US-0118381.
 XX
 PA (UTAH) UNIV UTAH RES FOUND.
 PA (COGN-) COGNETIX INC.
 XX
 PI Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM;
 XX
 PT WPI; 2000-505965/45.
 DR N-PSDB; AAA89423.
 XX
 PT alpha-conotoxin polypeptides derived from the venom of cone snails
 PT useful e.g. as neuromuscular blocking agents for use in surgery and for
 PT treating unipolar depression -
 XX
 PS Claim 39; Page 38; 229pp; English.
 XX
 CC The present invention relates to a number of alpha-conotoxin peptides and

CC their coding sequences from a number of different species of cone snail.
 CC These peptides are found in minute quantities in the venom of the snails,
 CC and are targeted at the neuronal nicotinic acetylcholine receptors of the
 CC nervous system. They usually contain two disulphide bonds, which give
 CC them defined conformations, a rarity in molecules this small. The
 CC alpha-conotoxins can be used as neuromuscular blocking agents in surgery,
 CC and for treating disorders regulated at the neuronal nicotinic
 CC acetylcholine receptors, including cardiovascular disorders, gastric
 CC motility disorders, urinary incontinence, nicotine addiction, mood
 CC disorders such as bipolar disorder, unipolar depression, dysthymia and
 CC seasonal affective disorder, and small cell lung carcinoma.
 XX
 SQ Sequence 63 AA;
 Query Match 84.0%; Score 100; DB 21; Length 63;
 Best Local Similarity 93.8%; Pred. No. 0.00013;
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCSNPVCCHLEHSNLC 16
 Db 44 GCCSNPVCCHLEHSNLC 59

Search completed: March 17, 2003, 07:23:41
 Job time : 21.3206 secs